Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Estramustine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.76 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.65 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 2/20 | 0.89 |
| ▸ | BLM | P54132 | 2/20 | 0.89 |
| ▸ | ESR1 | P03372 | 6/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.76 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.76 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.76 |
| ▸ | DRD1 | P21728 | 1/20 | 0.76 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.76 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 5/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | ATM | Q13315 | 2/20 | 0.65 |
| ▸ | PGR | P06401 | 2/20 | 0.65 |
| ▸ | AR | P10275 | 2/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.65 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estramustine SCHEMBL9509552 | 0.98 | RECQL (0.89) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL3974 | 0.98 | RECQL (0.89) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL19197890 | 0.98 | RECQL (0.92) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL2534637 | 0.98 | RECQL (0.87) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL17350515 | 0.98 | RECQL (0.90) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL8342744 | 0.96 | RECQL (0.93) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL22129748 | 0.96 | RECQL (0.93) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL3625800 | 0.96 | RECQL (0.93) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL36761 | 0.96 | RECQL (0.93) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL15710412 | 0.95 | RECQL (0.92) | RECQLBLMESR1ADORA3INPPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6107678-A | — | — | None | — | — | JP | disclosed |
| US-10161929-B2 | Theranostics platform and methods of use | Sanford Burnham Prebys Medical Discovery (US) | 2018-12-25 | — | — | US | disclosed |
| US-9549988-B2 | Pharmaceutical compounds targeted by MIF affinity-tethered moieties | RJS Biologics (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | RJS BIOLOGICS LLC | 2015-12-10 | — | — | US | disclosed |
| WO-2013123403-A1 | THERANOSTICS PLATFORM AND METHODS OF USE | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-08-22 | — | — | WO | disclosed |
| WO-2002039996-A2 | COMBINED THERAPY AGAINST TUMORS COMPRISING ESTRAMUSTINE PHOSPHATE AND LHRH AGONISTS OR ANTAGONISTS | PHARMACIA & UP JOHN COMPANY (US) | 2002-05-23 | — | — | WO | disclosed |
| CN-1031060-C | Process for producing novel esters | PHARMACIA AB (SE) | 1996-02-21 | — | — | CN | disclosed |
| JP-H06107678-A | PRODUCTION OF ESTRAMUSTINE PHOSPHATE DISODIUM SALT | SANKYO KASEI KOGYO KK | 1994-04-19 | — | — | JP | disclosed |
| EP-0351561-B1 | Novel esters of estramustine | KABI PHARMACIA AB (SE) | 1993-10-27 | — | — | EP | disclosed |
| US-5036062-A | Antitumor | PHARMACIA AB (SE) | 1991-07-30 | — | — | US | disclosed |
| CN-1045792-A | The manufacture method of esters | PHARMACIA AB (SE) | 1990-10-03 | — | — | CN | disclosed |
| EP-0351561-A1 | Novel esters of estramustine | Kabi Pharmacia AB (SE) | 1990-01-24 | — | — | EP | disclosed |
| US-4634691-A | BREAST, LUNG OR PROSTATE CANCER | THE PROCTER & GAMBLE COMPANY (US) | 1987-01-06 | — | — | US | disclosed |
| US-4115414-A | ESTRAMUSTINE PHOSPHATE ALCOHOL COMPLEXES, THEIR PREPARATION, AND THEIR USE AS INTERMEDIATES IN PURIFICATION OF SAID COMPOUND AND SALTS THEREOF | AKTIEBOLAGET LEO (SE) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | MIF, HMGB2, HMGB1 | KDR 442/4885ADRA1A 1819/4885OPRM1 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.